T follicular helper cells: linking cancer immunotherapy and immune-related adverse events

Cancer immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of numerous cancer types. As the underlying mechanism of these treatments lies in the interference with inhibitory signals that usually impair potent antitumor immunity, for example, cytotoxic T-lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumjohann, Dirk, Brossart, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194326/
https://www.ncbi.nlm.nih.gov/pubmed/34112740
http://dx.doi.org/10.1136/jitc-2021-002588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194326/
https://www.ncbi.nlm.nih.gov/pubmed/34112740
http://dx.doi.org/10.1136/jitc-2021-002588

Ejemplares similares